EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MiR‐548 K regulatory effect on the ABCG2 gene expression in MDR breast cancer cells

Mohammadreza Saberiyan, Zahra Ghasemi, Hajar Yaghoobi iD

Cancer Reports · 2023

DOI: 10.1002/cnr2.1816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2023. Verfasst von Mohammadreza Saberiyan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran. Hauptthemen laut MEDLINE: Breast Neoplasms, MicroRNAs. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shahrekord University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background multidrug resistance (MDR) is One of the foremost challenges in overcoming breast cancer. Various molecular processes are involved in the development of MDR in breast cancer cells, including over expression of ABC transporters such as ABCG2 ( BCRP ), increase breast cancer stem cells drug resistance, and epithelial mesenchymal transition.

Aims

In the present study, we used bioinformatics and experimental analysis to investigate the role of miR‐548 K, in the modulating of ABCG2, in MDR breast cancer cells. Methods and Results In silico inspections introduce 14 microRNAs targeting 3′‐UTR region of ABCG2 transcripts, which are probably involved in breast cancer drug resistance. An association was highlighted between miR‐548 k with ABC transporter family. The expression level of ABCG2 gene in MCF7‐MX cell lines was significantly more than MCF7 cell lines. On the other hand, we increased the expression of miR‐548 K in MCF7‐MX and MCF7 cell lines through its transfection, which dramatically coincided with decreasion in the ABCG2 transcripts level. Additional studies on patient samples revealed that the expression of ABCG2 showed an increase in ABCG2 level in neoadjuvant chemotherapy drugs resistance (NCDR) patients compared to primary pre‐operative chemotherapy drugs response (PCDR) patients. Also, a reduction in the expression of miR‐548 K in NCDR patients was revealed.

Conclusion

The results of our study suggest that miR‐548 K may be involved in modulating the expression of ABCG2 in MDR breast cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMicroRNAsHumansFemaleATP Binding Cassette Transporter, Subfamily G, Member 2Cell Line, TumorNeoplasm ProteinsDrug Resistance, MultipleATP-Binding Cassette TransportersGene Expression

Stichwörter der Autor:innen

ABCG2breast cancermiR-548 kmulti drug resistance

Substanzen

ATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsMicroRNAsATP-Binding Cassette TransportersABCG2 protein, humanMIRN548 microRNA, human

Autor:innen und Institutionen

  • Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
  • Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.
  • Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.

ORCID-Profile: Hajar Yaghoobi

Förderung

  • Shahrekord University of Medical Sciences

Zitieren

APA

Saberiyan, M., Ghasemi, Z., & Yaghoobi, H. (2023). MiR‐548 K regulatory effect on the ABCG2 gene expression in MDR breast cancer cells. Cancer Reports. https://doi.org/10.1002/cnr2.1816

Vancouver

Saberiyan M, Ghasemi Z, Yaghoobi H. MiR‐548 K regulatory effect on the ABCG2 gene expression in MDR breast cancer cells. Cancer Reports. 2023. doi:10.1002/cnr2.1816

BibTeX
@article{Saberiyan2023,
  author = {Saberiyan, Mohammadreza and Ghasemi, Zahra and Yaghoobi, Hajar},
  title = {MiR‐548 K regulatory effect on the ABCG2 gene expression in MDR breast cancer cells},
  journal = {Cancer Reports},
  year = {2023},
  doi = {10.1002/cnr2.1816}
}
Kostenlos starten →